Design Therapeutics DSGN Stock
Design Therapeutics Price Chart
Design Therapeutics DSGN Financial and Trading Overview
| Design Therapeutics stock price | 10.44 USD |
| Previous Close | 10.48 USD |
| Open | 10.41 USD |
| Bid | 7.61 USD x 200 |
| Ask | 13.05 USD x 200 |
| Day's Range | 10.11 - 10.78 USD |
| 52 Week Range | 3.33 - 17.25 USD |
| Volume | 1.5M USD |
| Avg. Volume | 656.13K USD |
| Market Cap | 652.05M USD |
| Beta (5Y Monthly) | 1.738 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21 USD |
DSGN Valuation Measures
| Enterprise Value | 434.46M USD |
| Trailing P/E | N/A |
| Forward P/E | -6.3825493 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.9896905 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -5.589 |
Trading Information
Design Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.738 |
| 52-Week Change | 160.69% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 17.25 USD |
| 52 Week Low | 3.33 USD |
| 50-Day Moving Average | 12.37 USD |
| 200-Day Moving Average | 9.21 USD |
DSGN Share Statistics
| Avg. Volume (3 month) | 656.13K USD |
| Avg. Daily Volume (10-Days) | 1.92M USD |
| Shares Outstanding | 62.46M |
| Float | 35.36M |
| Short Ratio | 4.89 |
| % Held by Insiders | 31.93% |
| % Held by Institutions | 61.33% |
| Shares Short | 2.9M |
| Short % of Float | 6.16% |
| Short % of Shares Outstanding | 4.65% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -20.93% |
| Return on Equity (ttm) | -31.26% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -58131000 USD |
| EBITDA | -77735000 USD |
| Net Income Avi to Common (ttm) | -69713000 USD |
| Diluted EPS (ttm) | -1.2 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 222.82M USD |
| Total Cash Per Share (mrq) | 3.57 USD |
| Total Debt (mrq) | 2.73M USD |
| Total Debt/Equity (mrq) | 1.25 USD |
| Current Ratio (mrq) | 22.282 |
| Book Value Per Share (mrq) | 3.492 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -54000000 USD |
| Levered Free Cash Flow (ttm) | -31555876 USD |
Profile of Design Therapeutics
| Country | United States |
| State | CA |
| City | Carlsbad |
| Address | 6005 Hidden Valley Road |
| ZIP | 92011 |
| Phone | 858 293 4900 |
| Website | https://www.designtx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 54 |
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
Q&A For Design Therapeutics Stock
What is a current DSGN stock price?
Design Therapeutics DSGN stock price today per share is 10.44 USD.
How to purchase Design Therapeutics stock?
You can buy DSGN shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Design Therapeutics?
The stock symbol or ticker of Design Therapeutics is DSGN.
Which industry does the Design Therapeutics company belong to?
The Design Therapeutics industry is Biotechnology.
How many shares does Design Therapeutics have in circulation?
The max supply of Design Therapeutics shares is 62.46M.
What is Design Therapeutics Price to Earnings Ratio (PE Ratio)?
Design Therapeutics PE Ratio is now.
What was Design Therapeutics earnings per share over the trailing 12 months (TTM)?
Design Therapeutics EPS is -1.2 USD over the trailing 12 months.
Which sector does the Design Therapeutics company belong to?
The Design Therapeutics sector is Healthcare.
Design Therapeutics DSGN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}